Author/Authors :
Hashempour Alamdari, Nasim Department of Radiopharmacy and Medicinal Chemistry - Pharmaceutical Sciences Branch - Islamic Azad University - Tehran, Iran , Alaei-Beirami, Mahmood Tabriz University of Medical Science - Tabriz, Iran , Sadat Shandiz, Ataollah Department of Biology - Central Tehran Branch - Islamic Azad University - Tehran, Iran , Hejazinia, Hadi Department of Radiopharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Rasouli, Rahimeh Department of Medical Nanotechnology - School of Medicine - International Campus - Tehran University of Medical Sciences - Tehran, Iran , Saffari, Mostafa Department of Medical Nanotechnology - School of Medicine - International Campus - Tehran University of Medical Sciences - Tehran, Iran , Sadat Ebrahimi, Esmaeil Department of Medicinal Chemistry - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Assadi, Artin Department of Radiopharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Shafiee Ardestani, Mehdi Department of Radiopharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran
Abstract :
Designing a unique theranostic biocompatible, biodegradable, and cost-effective agent which is easy to be synthesized as a biohybrid
material was the aim of this study. In this matter, asparagine attached to anionic linear globular dendrimer G2 (as a biocompatible,
biodegradable, and cost-effective agent which is negatively charged nanosized and water soluble polymer that outweighs other
traditionally used dendrimers) and finally contrast agent (Gd3+) was loaded (which made complexes) in synthesized asparaginedendrimer. Observations revealed that, in addition to successful colon cancer and brain targeting, Gd3+-dendrimer-asparagine,
the proposed theranostic agent, could increase T1 MR relaxation times, decrease T2 MR relaxation times significantly, and improve
contrast of image as well as illustrating good cellular uptake based on florescent microscopy/flow cytometry and ICP-mass data. In
addition to that, it increased tumor growth inhibition percentage (TGI%) significantly compared to FDA approved contrast agent,
Magnevist. Totally, Gd3+-anionic linear globular dendrimer G2-asparagine could be introduced to the cancer imaging/therapy
(theranostics) protocols after in vivo MR and fluorescent analysis and passing clinical trials. Hence, this nanotheranostic agent
would be a promising candidate for brain drug delivery and imaging in the future.
Keywords :
Gd3+ , Globular , Theranostics , Nanobiohybrid
